fenfluramine has been researched along with Cardiac Diseases in 5 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Precapillary pulmonary hypertension is defined by an increase in mPAP > or =25 mmHg and a pulmonary capillary wedge pressure (PCWP)< or =15 mmHg associated with a normal or reduced cardiac output." | 1.36 | [Diagnosis and classification of pulmonary hypertension]. ( Chaouat, A; Montani, D, 2010) |
| " The Ministry of Health has recently alerted practitioners to the possible risk of heart valve damage following the long-term use of weight-loss drugs fenfluramine (Ponderax) and dexfenfluramine (Adifax)." | 1.30 | Prevention of infective endocarditis associated with dental treatment and other medical interventions. National Heart Foundation. ( Ellis-Pegler, RB; Hay, KD; Lang, SD; Neutze, JM; Swinburn, BA, 1999) |
| " Statistical analysis of the results from 22 patients showed that there was no significant difference between prothrombin times and anticoagulant dosage in the period when patients were receiving benfluorex and the values recorded during the baseline and follow-up periods." | 1.26 | Co-administration of benfluorex with oral anticoagulant therapy. ( Brems, HM; De Witte, P, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cambon, D | 1 |
| Leclercq, F | 1 |
| Montani, D | 1 |
| Chaouat, A | 1 |
| De Witte, P | 1 |
| Brems, HM | 1 |
| Nightingale, SL | 1 |
| Ellis-Pegler, RB | 1 |
| Hay, KD | 1 |
| Lang, SD | 1 |
| Neutze, JM | 1 |
| Swinburn, BA | 1 |
5 other studies available for fenfluramine and Cardiac Diseases
| Article | Year |
|---|---|
Clinical and echographic characteristics of patients exposed to fenfluramin or its derivatives: Results of a prospective, single-centre, observational study.
Topics: Aged; Appetite Depressants; Dexfenfluramine; Female; Fenfluramine; Heart Diseases; Humans; Male; Pro | 2015 |
[Diagnosis and classification of pulmonary hypertension].
Topics: Activin Receptors, Type II; Anemia, Hemolytic; Bone Morphogenetic Protein Receptors, Type II; Cardia | 2010 |
Co-administration of benfluorex with oral anticoagulant therapy.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Drug Interactions; Female; Fenfluramine; Heart Di | 1980 |
From the Food and Drug Administration.
Topics: Appetite Depressants; Chemical and Drug Induced Liver Injury; Chromans; Drug Labeling; Fenfluramine; | 1997 |
Prevention of infective endocarditis associated with dental treatment and other medical interventions. National Heart Foundation.
Topics: Adult; Anti-Obesity Agents; Antibiotic Prophylaxis; Aortic Valve Insufficiency; Cefuroxime; Cephalos | 1999 |